Infliximab BS Nichiiko / AYUMI
Infliximab biosimilar developed by Nichi-Iko Pharmaceutical (with Ayumi Pharmaceutical). Reference product Remicade.
About Infliximab BS Nichiiko / AYUMI
Infliximab BS Nichiiko is Nichi-Iko's own infliximab, approved in Japan in September 2017 as the second infliximab biosimilar there, and also sold under the name of Ayumi Pharmaceutical. Nichi-Iko is one of the few Japanese generics companies to develop its own biosimilars.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan · Infliximab BS Nichiiko / AYUMI
Pharmaceuticals and Medical Devices Agency and MHLWApprovedCanada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Infliximab BS Nichiiko / AYUMI holds an approval, these are the other infliximab biosimilars approved in that market.
Same developer, other molecules
Other biosimilars in the Atlas developed by Nichi-Iko Pharmaceutical: Bevacizumab BS Nichi-Iko.
Chronology
- PMDASep 2017Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning infliximab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant